Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating expenses:
Research and development	$ 6,617	$ 3,478	$ 16,975	$ 6,071
General and administrative	4,832	4,008	9,852	6,881
Acquired in-process research and development				164,617
Total operating expenses	11,449	7,486	26,827	177,569
Loss from operations	(11,449)	(7,486)	(26,827)	(177,569)
Other income (expense):
Interest and investment income	214	40	269	53
Other expense, net	(15)	(20)	(16)	(34)
Total other income, net	199	20	253	19
Net loss	(11,250)	(7,466)	(26,574)	(177,550)
Dividend on convertible preferred stock related to beneficial conversion feature and issuance costs		(24,437)		(24,437)
Net loss attributable to common shareholders	$ (11,250)	$ (31,903)	$ (26,574)	$ (201,987)
Net loss per share - basic	$ (0.86)	$ (5.33)	$ (2.04)	$ (41.55)
Net loss per share - diluted	$ (0.86)	$ (5.33)	$ (2.04)	$ (41.55)
Weighted-average common shares outstanding used in net loss per share - basic	13,016,955	5,980,097	13,016,955	4,861,279
Weighted-average common shares outstanding used in net loss per share - diluted	13,016,955	5,980,097	13,016,955	4,861,279